- Home
- ACAD vs CENTA Comparison
ACAD vs CENTA Comparison
Compare ACAD & CENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- CENTA
- Stock Information
- Founded
- ACAD 1993
- CENTA 1955
- Country
- ACAD United States
- CENTA United States
- Employees
- ACAD N/A
- CENTA N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- CENTA Consumer Specialties
- Sector
- ACAD Health Care
- CENTA Consumer Discretionary
- Exchange
- ACAD Nasdaq
- CENTA Nasdaq
- Market Cap
- ACAD 2.5B
- CENTA 2.0B
- IPO Year
- ACAD 2004
- CENTA 1993
- Fundamental
- Price
- ACAD $22.71
- CENTA $30.44
- Analyst Decision
- ACAD Buy
- CENTA Buy
- Analyst Count
- ACAD 16
- CENTA 4
- Target Price
- ACAD $27.00
- CENTA $37.00
- AVG Volume (30 Days)
- ACAD 1.6M
- CENTA 310.7K
- Earning Date
- ACAD 08-05-2025
- CENTA 08-06-2025
- Dividend Yield
- ACAD N/A
- CENTA N/A
- EPS Growth
- ACAD N/A
- CENTA N/A
- EPS
- ACAD 1.37
- CENTA 1.87
- Revenue
- ACAD $996,283,000.00
- CENTA $3,155,810,000.00
- Revenue This Year
- ACAD $13.39
- CENTA $0.42
- Revenue Next Year
- ACAD $10.59
- CENTA $1.77
- P/E Ratio
- ACAD $16.65
- CENTA $15.98
- Revenue Growth
- ACAD 22.42
- CENTA N/A
- 52 Week Low
- ACAD $13.40
- CENTA $27.70
- 52 Week High
- ACAD $25.23
- CENTA $37.31
- Technical
- Relative Strength Index (RSI)
- ACAD 66.04
- CENTA 42.48
- Support Level
- ACAD $21.35
- CENTA $29.99
- Resistance Level
- ACAD $22.69
- CENTA $31.33
- Average True Range (ATR)
- ACAD 0.76
- CENTA 0.77
- MACD
- ACAD -0.13
- CENTA -0.17
- Stochastic Oscillator
- ACAD 70.76
- CENTA 18.29
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About CENTA Central Garden & Pet Company Nonvoting
Central Garden & Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.